InvestorWire NewsRoom


InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
December 6, 2022

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”). During his career, Dobbelstein has amassed impressive experience, particularly with his research, which has focused on principles of infections and cancer. He has studied the application of anticancer drugs as antivirals and has also worked with alpaca-derived NanoAbs, or nanosized antibodies known as nanobodies and VHH antibodies, as therapeutics. Dobbelstein and Dr. Dirk Görlich have provided research that serves as the scientific basis of BiondVax’s exclusive license for development and commercialization of an innovative, self-administered, inhaled NanoAb for the treatment of COVID-19, an approach that indicated significantly milder illness and faster recovery in a recent study. Dobbelstein and Görlich are collaborating with BiondVax to work toward the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration. “We have been enjoying productive scientific cooperation with Professor Dobbelstein over the past year through our collaboration to develop his and Professor Görlich’s translational NanoAb research into a drug candidate for the treatment of COVID-19, which is currently being tested in a preclinical study,” said BiondVax Pharmaceuticals chief science officer Dr. Tamar Ben-Yedidia in the press release. “On behalf of BiondVax’s executive team, I am pleased to welcome Matthias to our SAB and am confident his deep scientific and clinical knowledge will meaningfully contribute to further building BiondVax into an innovative multi-asset pharmaceutical company.”

In addition, BiondVas announced that it has chosen InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communications partner. According to the announcement, IBN will use its investor-based distribution network to generate greater awareness of the company; that network includes more than 5,000 syndication outlets as well as several newsletters, social media channels, wire services, blogs and other outreach tools. “BiondVax is guided by a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK and Bristol-Myers Squibb,” said IBN director of client solutions Chris Johnson in the press release. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it moves toward a phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023. The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected.”

To view the full press releases, visit and

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company also has a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).